Stuttgart
06.02.26 | 21:55
0,115 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,115 | 0,128 | 07.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 219 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| Mi | Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States | 220 | Business Wire | Building on Strong 2025 Momentum with Accelerated Sales Growth in Pancreatic Cysts €1M Milestone for CellTolerance Appointment of Benoit Chardon as Fractional Chief Commercial Officer to Lead... ► Artikel lesen | |
| 26.01. | Mauna Kea Technologies Announces Initiation of Coverage by Allinvest Securities | 193 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) announces today... ► Artikel lesen | |
| 21.01. | Mauna Kea Technologies Announces Its 2026 Financial Calendar Highlighted by Its Participation in Several Investor Forums | 237 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today... ► Artikel lesen | |
| 15.01. | Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. | 1.170 | Business Wire | Q4 2025 revenue up 19% on a reported basis (+29% excluding currency effects CER) Sales in the United States up 65% (+82% at CER) after three consecutive quarters of acceleration (+11%, +23%,... ► Artikel lesen | |
| 09.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 284 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.12.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 371 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 03.12.25 | Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management | 421 | Business Wire | Integrating Cellvizio into TaeWoong's portfolio of therapeutic devices to create the first fully integrated "imaging-to-therapy" solution for EUS-guided pancreatic care
Regulatory News:
Mauna... ► Artikel lesen | |
| 20.11.25 | Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio Platform | 492 | Business Wire | NMPA approval obtained following a 3-year certification process Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China independently of the JV with Tasly
Regulatory... ► Artikel lesen | |
| 17.11.25 | XFRA 1MK: WIEDERAUFNAHME/RESUMPTION | 255 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.11.25 | Mauna Kea Technologies: €6 Million Raised To Strengthen Long Term Growth | 2 | pulse2.com | ||
| 14.11.25 | Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise | 589 | Business Wire | 70% debt write-off, from €40M to €12M Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035 Capital raise of €6.1M extending cash runway to the second... ► Artikel lesen | |
| 13.11.25 | XFRA 1MK: AUSSETZUNG/SUSPENSION | 510 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAUNA KEA TECHNOL.EO... ► Artikel lesen | |
| 13.11.25 | Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise | 461 | Business Wire | Safeguard plan approved by judgment of the Paris Commercial Court on November 12, 2025 Launch of a reserved capital increase in the form of shares with attached warrants (ABSA) at a price of... ► Artikel lesen | |
| 06.11.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 350 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 21.10.25 | Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase | 475 | Business Wire | New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability The future exercise of share subscription warrants (BSA)... ► Artikel lesen | |
| 13.10.25 | Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates | 313 | Business Wire | U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year Commercial momentum highlighted by a doubling of U.S. system sales year-to-date Adding to U.S. commercial... ► Artikel lesen | |
| 08.10.25 | Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan | 614 | Business Wire | Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants (ABSA) Firm commitment from an investor for... ► Artikel lesen | |
| 06.10.25 | Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring | 1.237 | Business Wire | A large majority of creditors and shareholders have voted in favor of the draft safeguard plan This plan includes a 70% reduction in debt, from €40 million to €12 million, with a payment schedule... ► Artikel lesen | |
| 02.10.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 405 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,086 | -7,53 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| FAMICORD | 5,400 | 0,00 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,670 | -2,20 % | GERATHERM MEDICAL AG - Schwäche im aktuellen Marktumfeld | ||
| PLUS THERAPEUTICS | 0,256 | +10,65 % | Plus Therapeutics Inc.: Plus Therapeutics Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization | HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| MEDICLIN | 3,860 | -1,03 % | EQS-News: MEDICLIN AG: Dr. Joachim Ramming verlässt den Vorstand der MEDICLIN AG zum Ende des Geschäftsjahres 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Personalie
Dr. Joachim Ramming verlässt den Vorstand der MEDICLIN AG zum Ende des Geschäftsjahres 2025
16.12.2025 / 15:00 CET/CEST
Für... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 02.02.2026 | The following instruments on XETRA do have their first trading 02.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.02.2026
Aktien
1 CA00249P1053 AXA S.A. CDR
2 ARP125991090... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development | BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-K, Annual Report | ||
| VERU | 2,340 | +4,46 % | Veru Inc.: Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th | ||
| LIFEWARD | 0,570 | +5,01 % | Oramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic Transaction | Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD Technology) to Lifeward and Positions Oramed as a Significant Shareholder
Oramed will transfer... ► Artikel lesen | |
| LIGHT AI | 0,054 | -6,57 % | LIGHT AI INC im Fokus: Marktphase zeigt Korrekturzüge | ||
| EKSO BIONICS | 10,550 | +12,71 % | Applied Digital Corporation: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale | DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers mit einem Kursziel von 60 Euro auf "Buy" belassen. Der Aktienkurs der Münchner spiegle die mittelfristigen... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,115 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.